Brief: Cocrystal Pharma Announces Last Subject Dosed In Phase 1b Human Challenge Study Evaluating CDI-988 For Norovirus Prevention And Treatment
09/09/2026 12:33
BRIEF-Cocrystal Pharma Announces Last Subject Dosed In Phase 1b Human Challenge Study Evaluating CDI-988 For Norovirus Prevention And Treatment Sept 9 (Reuters) - Cocrystal Pharma Inc COCP.O:
COCRYSTAL PHARMA ANNOUNCES LAST SUBJECT DOSED IN PHASE 1B HUMAN CHALLENGE STUDY EVALUATING CDI-988 FOR NOROVIRUS PREVENTION AND TREATMENT
COCRYSTAL PHARMA - PRELIMINARY EFFICACY RESULTS FOR CDI-988 EXPECTED LATE 2026 OR EARLY 2027
COCRYSTAL PHARMA - NO SERIOUS ADVERSE EVENTS REPORTED TO DATE IN CDI-988 PHASE 1B STUDY
Source text: ID:nGNXbTp3Qn
Further company coverage: COCP.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cocrystal Pharma
See all newsBrief: Cocrystal Pharma Announces Last Subject Dosed In Phase 1b Human Challenge Study Evaluating CDI-988 For Norovirus Prevention And Treatment
Cocrystal Pharma Inc reports results for the quarter ended June 30 - Earnings Summary
Cocrystal Pharma Inc expected to post a loss of 16 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Medtronic, Macy's, USA Rare Earth
U.S. STOCKS ON THE MOVE-USA Rare Earth, MiniMed, Rent the Runway